Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/29085| Title: | Perspectives of Patients With Rheumatic Diseases in the Early Phase of COVID-19. | Authors: | Antony A. ;Connelly K. ;De Silva T.;Eades L.;Tillett W.;Morand E. ;Ayoub S. | Monash Health Department(s): | Monash University - School of Clinical Sciences at Monash Health Rheumatology |
Institution: | (Antony, Connelly, Ayoub, Morand) School of Clinical Sciences, Monash University, and Monash Health, VIC, Australia (De Silva, Eades) Monash Health, VIC, Australia (Tillett) Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Trust, and University of Bath, Bath, United Kingdom | Issue Date: | 7-Sep-2020 | Copyright year: | 2020 | Publisher: | John Wiley and Sons Inc. (P.O.Box 18667, Newark NJ 07191-8667, United States) | Place of publication: | United States | Publication information: | Arthritis Care and Research. 72 (9) (pp 1189-1195), 2020. Date of Publication: 01 Sep 2020. | Journal: | Arthritis Care and Research | Abstract: | Objective: To determine health perceptions of patients with rheumatic diseases in the early phase of the coronavirus disease 2019 (COVID-19) pandemic. Method(s): Rheumatology patients at a single center received via text message the Australian Rheumatology Association COVID-19 information sheet and an invitation to participate in a deidentified survey. Patient concerns regarding risks conferred by their rheumatologic disease or medications, impact of receiving the information sheet on the likelihood of staying on medication, and acceptance of telehealth were ascertained. Result(s): A total of 2,630 patients received the text message, and the survey response rate was 21% (n = 550). The mean +/- SD age of the participants was 52 +/- 15.2 years, and 75.3% were female. Participants' highest ranked concern was that their medications would increase the severity of their COVID-19 symptoms (76.1%). The highest levels of concern were seen in patients taking combination conventional synthetic disease-modifying antirheumatic drugs (DMARDs) and/or a biologic/targeted synthetic DMARD. There was no association between prednisolone dose and concern. While 63% of patients planned to continue their antirheumatic medications, a further 30% were more likely to continue taking their medications because of receiving the information. Telehealth was acceptable to 98.4% of patients, but 28.1% felt this was only appropriate while infection control measures were in place. Conclusion(s): Concerns regarding the risk of COVID-19 among patients taking antirheumatic drugs are common. Proactive dissemination of information is needed to address misconceptions related to medication risk, improve medication adherence, and minimize the risk of flares. Telehealth is acceptable to most patients during the COVID-19 pandemic.Copyright © 2020, American College of Rheumatology | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1002/acr.24347 | PubMed URL: | 32526068 [http://www.ncbi.nlm.nih.gov/pubmed/?term=32526068] | ISSN: | 2151-464X | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/29085 | Type: | Article | Subjects: | psoriatic arthritis/di [Diagnosis] psoriatic arthritis/dt [Drug Therapy] *rheumatic disease rheumatoid arthritis/di [Diagnosis] rheumatoid arthritis/dt [Drug Therapy] rheumatology scleroderma/di [Diagnosis] scleroderma/dt [Drug Therapy] social acceptance spondylarthritis/di [Diagnosis] spondylarthritis/dt [Drug Therapy] systemic lupus erythematosus/di [Diagnosis] systemic lupus erythematosus/dt [Drug Therapy] telehealth therapeutic misconception vasculitis/di [Diagnosis] vasculitis/dt [Drug Therapy] abatacept/dt [Drug Therapy] azathioprine/dt [Drug Therapy] cyclophosphamide/dt [Drug Therapy] cyclosporine/dt [Drug Therapy] hydroxychloroquine/dt [Drug Therapy] Janus kinase inhibitor/dt [Drug Therapy] leflunomide/dt [Drug Therapy] methotrexate/dt [Drug Therapy] mycophenolic acid/dt [Drug Therapy] nonsteroid antiinflammatory agent/dt [Drug Therapy] prednisolone/dt [Drug Therapy] rituximab/dt [Drug Therapy] salazosulfapyridine/dt [Drug Therapy] secukinumab/dt [Drug Therapy] tacrolimus/dt [Drug Therapy] tocilizumab/dt [Drug Therapy] tumor necrosis factor inhibitor/dt [Drug Therapy] ustekinumab/dt [Drug Therapy] infection control adult article controlled study *coronavirus disease 2019/di [Diagnosis] *coronavirus disease 2019/dt [Drug Therapy] *disease course disease severity drug use female health survey human major clinical study male medical information middle aged pandemic patient participation patient risk *perception psoriatic arthritis rheumatic disease rheumatoid arthritis rheumatology scleroderma social acceptance spondylarthritis systemic lupus erythematosus telehealth therapeutic misconception vasculitis abatacept azathioprine cyclophosphamide cyclosporine hydroxychloroquine Janus kinase inhibitor leflunomide methotrexate mycophenolic acid nonsteroid antiinflammatory agent prednisolone rituximab salazosulfapyridine secukinumab tacrolimus tocilizumab tumor necrosis factor inhibitor ustekinumab infection control coronavirus disease 2019 disease course drug use health survey medical information pandemic patient participation patient risk perception medical information middle aged pandemic patient participation patient risk *perception psoriatic arthritis / diagnosis / drug therapy *rheumatic disease rheumatoid arthritis / diagnosis / drug therapy rheumatology scleroderma / diagnosis / drug therapy social acceptance spondylarthritis / diagnosis / drug therapy systemic lupus erythematosus / diagnosis / drug therapy telehealth therapeutic misconception vasculitis / diagnosis / drug therapy *coronavirus disease 2019 / *diagnosis / *drug therapy Article adult controlled study *disease course disease severity drug use female health survey human infection control major clinical study male |
| Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.